Latest Convertible Notes News

Life360 reported record Q2 2025 results with robust subscription growth and raised full-year guidance, alongside a strategic leadership transition appointing Lauren Antonoff as CEO.

Life360, Inc. reported a return to profitability in Q2 2025, driven by strong subscription growth and strategic partnerships, while also announcing a leadership transition and issuing $320 million in convertible notes.

Livium Ltd and Mineral Resources Ltd have formalised a 50 – 50 joint venture to commercialise the innovative LieNA® lithium processing technology, aiming to license it globally despite current market headwinds.

DigitalX Limited has announced a bold strategy to increase its Bitcoin holdings more than fourfold by the end of 2027, reinforcing its position as a leading Australian digital asset manager.

Block, Inc. reported a 2% decline in net revenue for Q2 2025, driven by lower bitcoin revenue despite growth in transaction and subscription services. The company posted strong net income and continued its $4 billion share repurchase program.

Clime Capital Limited reports an unaudited $3 million profit for FY25, plans a September dividend, and kicks off FY26 with a profitable July.

Adslot Ltd has raised nearly $1 million through a mix of secured convertible notes and a private share placement, aiming to strengthen its balance sheet and fund key projects. Shareholder approval and ASX waivers remain pivotal next steps.

Clime Capital Limited has launched a new Convertible Redeemable Notes offer featuring a 6.5% fixed annual interest rate, providing investors with monthly income and conversion flexibility.

Nutritional Growth Solutions Ltd (NGS) has had its trading suspension lifted following a key announcement about a capital raising, signaling renewed market activity.

Nutritional Growth Solutions revises its Q2 FY25 financials, confirming stable revenue and detailing expanded distribution into CVS and Walmart. The company is actively raising capital to support growth and improve liquidity.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.